Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

M. Anstee, Quentin; Jean Lucas, Kathryn; Francque, Sven; F. Abdelmalek, Manal; J. Sanyal, Arun; Ratziu, Vlad; Gadano, Adrián; E. Rinella, Mary; Charlton, Michael; Loomba, Rohit; Mena, Edward; M. Schattenberg, Jörn; Noureddin, Mazen; J. Lazas, Donald; Boon‐Bee Goh, George; K. Sarin, Shiv; Yılmaz, Yusuf; Martić, Miljen; Stringer, Rowan; Kochuparampil, Jossy; Chen, Li; Rodriguez‐Araujo, Gerardo; Chng, Elaine; V. Naoumov, Nikolai; A. Brass, Clifford; Pedrosa, Marcos

doi:10.1097/hep.0000000000000439

Public

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

Published in Hepatology • May 10, 2023

Authors:

Quentin M. Anstee

Kathryn Jean Lucas

Sven Francque

Abstract

BACKGROUND AND AIMS: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study assessed the safety and efficacy of TXR and CVC combination, compared with respe...

Subject

Medicine

Internal medicine

Gastroenterology

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!